153 related articles for article (PubMed ID: 3688000)
1. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
Mangan FR; Flack JD; Jackson D
Am J Med; 1987 Oct; 83(4B):6-10. PubMed ID: 3688000
[TBL] [Abstract][Full Text] [Related]
2. The unique pharmacologic profile of nabumetone.
Blower PR
J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
[TBL] [Abstract][Full Text] [Related]
3. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Friedel HA; Langtry HD; Buckley MM
Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
[TBL] [Abstract][Full Text] [Related]
4. Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
Dahl SL
Ann Pharmacother; 1993 Apr; 27(4):456-63. PubMed ID: 8477124
[TBL] [Abstract][Full Text] [Related]
5. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
[TBL] [Abstract][Full Text] [Related]
6. Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.
Bannwarth B
Drug Saf; 2008; 31(6):485-503. PubMed ID: 18484783
[TBL] [Abstract][Full Text] [Related]
7. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
Soma LR; Uboh CE; Rudy JA; Smith MS
Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
[TBL] [Abstract][Full Text] [Related]
8. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
[TBL] [Abstract][Full Text] [Related]
9. Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
Friedel HA; Todd PA
Drugs; 1988 May; 35(5):504-24. PubMed ID: 3293969
[TBL] [Abstract][Full Text] [Related]
10. [Properties and features of nabumetone].
Davies NM; McLachlan AJ
Drugs; 2000; 59 Spec No 1():25-33. PubMed ID: 10841070
[TBL] [Abstract][Full Text] [Related]
11. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
12. Nabumetone (Relifex)--another NSAID.
Drug Ther Bull; 1988 May; 26(11):41-3. PubMed ID: 3289871
[No Abstract] [Full Text] [Related]
13. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
14. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
Melarange R; Spangler R; Hoult JR
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
[TBL] [Abstract][Full Text] [Related]
15. An overview of the clinical pharmacokinetics of nabumetone.
Hyneck ML
J Rheumatol Suppl; 1992 Nov; 36():20-4. PubMed ID: 1474531
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
[TBL] [Abstract][Full Text] [Related]
17. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence study of nabumetone: tablet versus suspension.
Daigneault EA; Ferslew KE; Stanton P
Am J Med; 1987 Oct; 83(4B):11-4. PubMed ID: 3687999
[TBL] [Abstract][Full Text] [Related]
19. Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new anti-inflammatory agent.
Boyle EA; Freeman PC; Mangan FR; Thomson MJ
J Pharm Pharmacol; 1982 Sep; 34(9):562-9. PubMed ID: 6127380
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
